Advaxis Completes Patient Enrollment for Cancer Vaccine
Posted on: Tuesday, 1 May 2007, 06:00 CDT
US biotech company Advaxis has completed patient recruitment for the phase I/II trial of Lovaxin C, a Listeria-based immunotherapy for cervical cancer.
The patient enrollment commenced after dosing 15 patients in an escalating dose clinical trial that was conducted in Mexico, Serbia and Israel. The objective of this trial was to establish a range of safe doses up to a maximally tolerated dose, which has been achieved.
Advaxis plans to complete patient reporting in July, report the results over the following 2 months, and submit an IND for Lovaxin C to the FDA by October, 2007. If the IND is approved, it would be followed by additional phase II clinical trials in the US and internationally.
New Jersey-based Advaxis is developing therapeutic cancer vaccines that enhance the immune system's cancer-fighting abilities through its proprietary Listeria monocytogenes based system, which utilizes two immunological mechanisms (innate and classical immunity) to develop safer and more effective Listeria based cancer vaccines.
Source: Datamonitor
Related Articles
- Generex Biotechnology Phase I Trial Results for Novel Immunotherapy Vaccine in Breast Cancer Patients Presented At ASCO
- First Prostate Cancer Patients Treated in a Phase I Clinical Trial As Part of a Collaboration Between Generex Biotechnology and the Saint Savas Cancer Hospital
- Array BioPharma Advances ErbB-2 Inhibitor, ARRY-380, into Phase 1 Cancer Patient Trial
- Array BioPharma Advances P38 Inhibitor, ARRY-797, into Phase 1 Cancer Patient Trial
- Affymax Presents Results From Ongoing Phase 2 Clinical Trial of Hematide(TM) in Anemic Cancer Patients Receiving Chemotherapy
- VIDEO From Medialink: Scientists Have Launched a Clinical Trial That Could Ultimately Allow Doctors to Tailor Treatment for Cancer Patients
- Huge Trial Seeks Lowest Chemo Need: 10,000 Breast Cancer Patients Sought to Test Relapse Over 10 Years
- Trial Shows New Drug May Help Cancer Patients Who Need Stem Cell Transplants
- Peregrine Pharmaceuticals Opens Patient Enrollment for Its Tarvacin(TM) Phase I Solid Cancer Therapy Clinical Trial
- A.P. Pharma Initiates APF530 Phase 2 Clinical Trial Program in Cancer Patients
 |
 |
User Comments (0)
RSS Feeds